Latest Medifocus Inc. (MDFZF) Headlines Medif
Post# of 27
Posted On: 03/10/2014 1:05:24 PM
Latest Medifocus Inc. (MDFZF) Headlines
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
Medifocus Inc. Announces Closing of First Tranche of $3,540,000 Convertible Debenture Financing
Marketwire - Wed Dec 18, 8:17AM CST
Medifocus Inc. (OTCQX: MDFZF)(TSX VENTURE: MFS) announced today the initial closing of a non-brokered private placement of 354 units at a price of $10,000 per unit (the Units). The $3,540,000 is part of the Company's non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company expects to complete the remainder of the Offering on or before January 17, 2014.
Medifocus, Inc. Announces, VM Medical Center in Montreal Has Successfully Treated Its First Patient in Its Pivotal Phase III Clinical Trial for Breast Cancer Treatment
Marketwire Canada - Wed Dec 11, 9:13AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R. Keyserlingk, MD is the Principal Investigator at the VM Medical Center in Montreal, Canada. The VM Medical Center is the largest non-public private breast center in Canada.
Medifocus Inc. Announces Record 294% Increase in Q2/FY 2014 Revenue
Marketwire Canada - Wed Dec 04, 8:21AM CST
Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the use of focused microwave energy to treat cancer and other tumors, is pleased to announce its financial results for the three and six month periods of fiscal 2014 ending September 30, 2013.
Medifocus, Inc. Announces Joint Venture With Ideal Concept Group, Ltd in Hong Kong to Expedite the Company's Product Entry Into the Greater China and the Asia Pacific Marketplaces
Marketwire Canada - Tue Nov 12, 8:27AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that it has entered into a joint venture agreement with Ideal Concept Group, Ltd. (ICG), a Hong Kong-based company with extensive expertise in business development in Greater China and other Asia Pacific countries. Under the terms of the joint venture agreement, ICG and Medifocus will own 60% and 40% of the Joint Venture (JV), respectively.
Medifocus Inc. Announces Extension of Units Offering
Marketwire - Tue Oct 08, 6:01AM CDT
Medifocus Inc. (Medifocus) (TSX VENTURE: MFS)(OTCQX: MDFXF) announces that, further to its August 8, 2013 press release, it has extended its previously announced offering of units. Subject to regulatory approval, Medifocus is offering up to $6,000,000 worth of units (the Units) at a price of $10,000 per Unit by way of a non-brokered private placement (the Offering). Each Unit consists of (i) redeemable promissory notes, bearing 8% annual interest payable on a quarterly basis (Notes), which are convertible into common shares (Common Shares) at a conversion price of $0.25 per Common Share, and which are payable 36 months after the closing of the Offering; and (ii) Common Share purchase warrants to purchase up to one-half the number of Common Shares resulting from such conversion (Series C Warrants). Each whole Series C Warrant will entitle the holder to purchase one additional Common Share at a price of $0.30 per Common Share for a period of 36 months following the completion of the Offering.
Medifocus, Inc. Announces Revenue and Results of Operations for Fiscal First Quarter 2014
Marketwire - Thu Aug 29, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the use of focused microwave energy to treat cancer and other tumors, is pleased to announce its financial results for its first fiscal quarter of 2014 ended June 30, 2013. These results reflect the continued successful rollout of the Company's Prolieve(R) Thermodilatation System which is designed to provide a well-tolerated and effective alternative to drug therapy and certain types of surgical procedures used to treat the symptoms of Benign Prostatic Hyperplasia (BPH).
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
Medifocus Inc. Announces Closing of First Tranche of $3,540,000 Convertible Debenture Financing
Marketwire - Wed Dec 18, 8:17AM CST
Medifocus Inc. (OTCQX: MDFZF)(TSX VENTURE: MFS) announced today the initial closing of a non-brokered private placement of 354 units at a price of $10,000 per unit (the Units). The $3,540,000 is part of the Company's non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company expects to complete the remainder of the Offering on or before January 17, 2014.
Medifocus, Inc. Announces, VM Medical Center in Montreal Has Successfully Treated Its First Patient in Its Pivotal Phase III Clinical Trial for Breast Cancer Treatment
Marketwire Canada - Wed Dec 11, 9:13AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R. Keyserlingk, MD is the Principal Investigator at the VM Medical Center in Montreal, Canada. The VM Medical Center is the largest non-public private breast center in Canada.
Medifocus Inc. Announces Record 294% Increase in Q2/FY 2014 Revenue
Marketwire Canada - Wed Dec 04, 8:21AM CST
Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the use of focused microwave energy to treat cancer and other tumors, is pleased to announce its financial results for the three and six month periods of fiscal 2014 ending September 30, 2013.
Medifocus, Inc. Announces Joint Venture With Ideal Concept Group, Ltd in Hong Kong to Expedite the Company's Product Entry Into the Greater China and the Asia Pacific Marketplaces
Marketwire Canada - Tue Nov 12, 8:27AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that it has entered into a joint venture agreement with Ideal Concept Group, Ltd. (ICG), a Hong Kong-based company with extensive expertise in business development in Greater China and other Asia Pacific countries. Under the terms of the joint venture agreement, ICG and Medifocus will own 60% and 40% of the Joint Venture (JV), respectively.
Medifocus Inc. Announces Extension of Units Offering
Marketwire - Tue Oct 08, 6:01AM CDT
Medifocus Inc. (Medifocus) (TSX VENTURE: MFS)(OTCQX: MDFXF) announces that, further to its August 8, 2013 press release, it has extended its previously announced offering of units. Subject to regulatory approval, Medifocus is offering up to $6,000,000 worth of units (the Units) at a price of $10,000 per Unit by way of a non-brokered private placement (the Offering). Each Unit consists of (i) redeemable promissory notes, bearing 8% annual interest payable on a quarterly basis (Notes), which are convertible into common shares (Common Shares) at a conversion price of $0.25 per Common Share, and which are payable 36 months after the closing of the Offering; and (ii) Common Share purchase warrants to purchase up to one-half the number of Common Shares resulting from such conversion (Series C Warrants). Each whole Series C Warrant will entitle the holder to purchase one additional Common Share at a price of $0.30 per Common Share for a period of 36 months following the completion of the Offering.
Medifocus, Inc. Announces Revenue and Results of Operations for Fiscal First Quarter 2014
Marketwire - Thu Aug 29, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the use of focused microwave energy to treat cancer and other tumors, is pleased to announce its financial results for its first fiscal quarter of 2014 ended June 30, 2013. These results reflect the continued successful rollout of the Company's Prolieve(R) Thermodilatation System which is designed to provide a well-tolerated and effective alternative to drug therapy and certain types of surgical procedures used to treat the symptoms of Benign Prostatic Hyperplasia (BPH).
(0)
(0)Medifocus Inc. (MDFZF) Stock Research Links
Scroll down for more posts ▼